New Drug Shows Promise for Kidney Transplant Recipients in Clinical Trials
New clinical data on the experimental drug Tegoprubart show promising results in maintaining kidney transplant function and reducing side effects over two years, earning the therapy FDA Fast Track designation.
A promising new treatment could significantly alter the future management of kidney transplant recipients. Recent data presented at the international transplantation congress in Sydney, Australia, highlights encouraging results for the experimental drug Tegoprubart.
According to the findings, patients who received the medication maintained higher renal function over a two-year period compared to those receiving standard care. The U.S. Food and Drug Administration (FDA) has granted the drug Fast Track designation to expedite its development and evaluation processes.
The Challenge: Preventing Rejection Without Damaging Function
Kidney transplantation allows many patients with kidney failure to break free from dialysis dependence and improve their quality of life. However, even after a successful transplant, the body may recognize the new organ as foreign and attack it.
To prevent rejection, recipients must take immunosuppressive drugs for life. A common current medication is Tacrolimus, which helps prevent graft rejection but can cause side effects such as kidney damage, tremors, and metabolic disorders. Consequently, a core objective in transplant research is developing therapies that prevent rejection while minimizing side effects and preserving long-term kidney function.
Promising Results and Remaining Limitations
Developed by American biotechnology company Eledon Pharmaceuticals, Tegoprubart is a monoclonal antibody that blocks the CD40L protein, which is involved in activating the immune system. In a Phase 2 trial involving 127 kidney transplant recipients, patients receiving the experimental drug showed favorable outcomes, including a significantly lower incidence of new-onset diabetes post-transplant (about 2%) compared to the standard Tacrolimus group (about 17%).
"The experimental drug demonstrated encouraging results in preserving kidney function and reducing specific side effects over two years, though further large-scale studies are required to confirm its long-term safety and efficacy."
Despite the positive findings, important limitations remain. In the initial one-year analysis, no statistically significant difference was found in the primary measure of kidney function. Furthermore, the overall rate of acute rejection across all biopsies was 20.6% in the experimental group compared to 14.1% in the standard care group.
Looking Ahead to Phase 3 Trials
Following these data, the FDA granted the drug Fast Track status, though this represents an accelerated development pathway rather than a marketing approval. Eledon plans to launch a large international Phase 3 study named LEGACY in the final quarter of 2026, which is expected to enroll approximately 600 kidney transplant recipients to definitively assess the therapy's efficacy.
